Reviewer's report

Title: Potential Angiogenic Effect Of HCG In Rapid Progression And Spontaneous Regression Of Metastatic Renal Cell Carcinoma During Pregnancy And After Interruption. A case report.

Version: 4 Date: 24 August 2015

Reviewer: Krzysztof Tupikowski

Reviewer's report:

Dear Editors

I had an opportunity to review the manuscript: Potential antiangiogenic effect of HCG in rapid progression and spontaneous regression of metastatic renal cell carcinoma during pregnancy and after interruption. A case report. This is a nicely written report with some valuable information gathered in one manuscript. It is of interest for urologists, obstetricians and oncologists as such patients are very rare, clinical situation is extremely difficult (I have been in such myself) and each report is valuable because of that. References are generally well selected and up to date. Discussion is clear and delivers the message and valuable information.

I have some suggestions that might add some value to this manuscript:
- it is unclear to me if pregnancy and contraception methods have been discussed with the patient during systemic therapy or before its initiation; in my opinion it is important to underline it in the manuscript. If it was not discussed it might be a malpractice - MAJOR
- Which interferon was used for the treatment? - MINOR
- there are several reports (I am aware of 7 additional cases in 4 publications) of metastatic kidney cancer during pregnancy; it might be interesting to mention them in the manuscript or if word count allows to analyze them further:
  JAOA 1989; 89(7): 929-32
  Obstet Gynecol 1994; 83(5): 818-20
  Eur J Gynaec Oncol 1998; 19(6): 584-7

In my opinion this manuscript is worth publishing after changes.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:

My conflicts of interest: consultant for Pfizer, no other competing interests.